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Conclusions: The potential of the contrast enhancement 
method in increasing the applicability of markerless lung 
tumour tracking based on kV imaging was demonstrated on 
clinical data. A time-resolved (4D) CT scan can be used 
instead of the breath-hold CT scan available for this study in 
order to improve the robustness in the background 
subtraction operation, especially in case of lower lobe 
tumours for the compensation of diaphragm motion due to 
breathing. 
[1] Yang Y et al, IJROBP 2012;82:e749-56. 
[2] Spadea MF et al, IJROBP 2014;90:628-36. 
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Purpose/Objective: The purpose of this study is to evaluate 
the feasibility of markerless tumor detection using sequential 
dual-energy fluoroscopy sequences. As fast-switching kilovolt 
(kV) generators are not readily available, motion artifacts 
due to a time lapse between high and low energy images are 
often a cause for concern. For those kV generators without 
rapid switching, an alternative approach is proposed 
consisting of using sequential (high and low kV) high frame 
rate fluoroscopy sequences, already available in the clinical 
dynamic tracking (DT) workflow of the Vero SBRT system to 
build the hybrid correlation model. 
Materials and Methods: Two sequential 20s (11 Hz) 
fluoroscopy sequences were acquired at the start of one 
fraction for 4 patients treated for primary NSCLC with DT on 
the Vero SBRT system. Two sequences were acquired, using 2 
on-board kV imaging systems located at ± 45° from the MV 
beam axis, at respectively 60 kV (3.2 mAs) and 120 kV (2.0 
mAs). Table 1 shows the kV imager positions, which were 
selected based on marker visibility. Offline, a normalized 
cross-correlation algorithm was applied to anatomically 
match the high (HE) and low energy (LE) images. Per 
breathing phase (inhale, exhale, maximum inhale and 
maximum exhale), the five best matching HE and LE couples 
were extracted for dual energy subtraction. A validation on 
an anthropomorphic phantom with an imposed artificial 
tumor volume was conducted to validate the dual-energy 
approach. A contrast analysis according to gross tumor 
volume (GTV) was conducted between the DE and HE images 
based on contrast to noise ratio. Improved tumor visibility 
was quantified in function of 4 breathing phases using an 
improvement ratio (IR=CNRDE/CNRHE). 
Results: The additional acquisition of a 60 kV fluoroscopy 
sequence enabled an unambiguous approach to dual-energy 
imaging into the clinical workflow. Normalized cross 
correlation for HE-LE fluoroscopy sequence matching resulted 
in a mean correlation coefficient of 0.92 ± 0.18 based on the 
5 best anatomical HE-LE matches per breathing phase. 
Contrast to noise ratio’s (CNR) per patient can be found in 
Table 1. Bone suppression by DE subtraction imaging was 
successful. An example is shown in Figure 1. Based on the 
CNR, with the exception of one imaging angle the DE images 
showed no significantly improved tumor visibility compared 
to the HE images, with an improvement ratio averaged over 
all patients of 1.00 ± 0.50. 
Conclusions: Dual-energy subtraction imaging by sequential 
orthogonal fluoroscopy was shown feasible by implementing 
an additional LE fluoroscopy sequence into the DT workflow. 
However, for most imaging angles, dual-energy images 
showed no significantly improved tumor visibility over HE 
imaging. 
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Purpose/Objective: Real-time adaptive radiotherapy aims to 
improve radiation treatment through re-optimisation of 
treatment delivery based on patient-specific changes in 
anatomy and biology during treatments. MLC tracking is one 
real-time adaptive strategy that applies real-time tumour 
localisation to adapt the MLC shape during treatment. MLC 
tracking has been shown to be feasible for prostate cancer 
treatment on a standard linac, leading to improved tumour 
dose conformity, reduced rectal dose and improved fidelity 
of the planned treatment compared to standard delivery. 
Patient specific quality assurance of MLC tracking treatment 
is complex due to daily variation in tumour motion track 
creating new adaptations each day. We propose a high 
temporal and spatial resolution dosimetry system to verify 
the performance of MLC tracking.  
Materials and Methods: A monolithic silicon detector, known 
as MagicPlate-512 (MP512), has been developed and 
comprises 512 pixels arranged in a square array with sensitive 
volume 0.5x0.5x0.1mm3 and pitch 2mm. The array allows 
high resolution dose mapping and dose profiling in 2D. The 
MP512 is read out by a data acquisition system (DAS) 
synchronised with the electron gun pulses of the linac for 
pulse by pulse resolution of the dose delivered by the 
treatment beam. The detector is embedded in a solid water 
phantom and installed on a movable platform. The platform 
is supplied with a patient-specific motion pattern to replicate 
tumour motion. An electromagnetic positioning system 
provides real time position information to the MLC tracking 
software. The dose delivered by a static gantry with MLC 
defined square fields of sizes 1x1, 2x2 and 3x3cm2 is 
measured by MP512 and compared to EBT3 film for cases 
without motion, with motion and with motion and MLC 
tracking enabled. The DAS enables verification of dose 
variation pulse by pulse for each pixel, providing an insight 
into beam delivery for optimisation or debugging of a plan. 
Results: The beam profiles along the y-axis of the detector 
are compared to the EBT3 film for the three motion cases for 
the 2x2cm2 MLC defined field. 
 
 
The penumbral width (80-20%) and full-width at half-
maximum is measured for each profile for the field sizes and 
motion cases, the results benchmarked by EBT3 film. 
 
 
 
Conclusions: The results measured by the MP512 show 
excellent agreement with EBT3 film. The motion is observed 
to smear the profile of the beam. MP512 and EBT3 are able 
to reconstruct the distortion within 0.2mm; with MLC 
tracking enabled the smearing is reduced with a good 
agreement between no-motion and motion-tracking. The 
MP512 detector has proven to be an effective tool for pre-
treatment verification of real-time adaptive deliveries with 
both high spatial resolution for dose profiling and high 
temporal resolution for pulse by pulse reconstruction. 
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Purpose/Objective: The objective of this study was to 
directly measure and compare kQ factors [1] of reference 
type ionization chambers in flattening-filter (FF) and 
flattening-filter-free (FFF) clinical photon beams with 
nominal energies of 6 and 10 MV. 
Materials and Methods: Eight Baldwin-Farmer type ionization 
chambers (2×PTW 30013, 3×NE 2571, 3×PTW 30012) were 
calibrated in terms of absorbed-dose-to-water, Dw, in 60Co at 
VSL and in four clinical photon beams of 6 and 10 MV, both FF 
and FFF of an Elekta Versa HD at the Netherlands Cancer 
Institute. The absorbed-dose-to water was determined with 
the new VSL water calorimeter, designed for on-site 
measurements in clinical teletherapy beams (see Figure). 
Two waterproof ionization chambers (PTW 30013) were 
directly calibrated inside the water calorimeter thermostat. 
The other six ionization chambers (not waterproof) were 
cross-calibrated in a reference phantom against the PTW 
30013 chambers. Both the calorimeter and chamber 
measurements were performed against an external 
transmission monitor, placed on the accelerator tray. 
Measurements were corrected for radial non-uniformity due 
to the lateral beam profile with respect to the measurement 
point in the water calorimeter and the measurement volume 
of the ionization chamber. 
The FF and FFF beams of the same nominal energy were 
matched with respect to pdd(10). Based on pdd(10) the 
measured kQ factors in the two FFF beams were compared 
directly with the FF beams of the same nominal energy. 
Additionally a comparison between kQ factors in FFF and FF 
beams based on quality index TPR20,10 for both beams was 
